| Date Checked | 2025-12-21 23:37:03 |
|---|---|
| Graham Number | (PB)20.78 vs (PE)31.59 |
| Over / Under Value Percentage | 94.41% vs 42.34% |
| Dividend Yield | 0.00% |
| Dividend Date | None |
| Symbol | EXEL |
| AssetType | Common Stock |
| Name | Exelixis Inc |
| Description | Exelixis, Inc. is a leading biotechnology company headquartered in Alameda, California, dedicated to the discovery and development of innovative cancer therapies. With a strong portfolio of approved treatments and a dynamic drug pipeline, Exelixis prioritizes oncology to address significant unmet medical needs in cancer care. The company's commitment to enhancing patient outcomes is supported by its advanced research and development capabilities, solidifying its position as a key player in the biopharmaceutical industry. By continuously focusing on transformative solutions, Exelixis aims to improve the quality of life for cancer patients while driving sustainable growth and value for investors. |
| CIK | 939767 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | BIOTECHNOLOGY |
| Address | 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, UNITED STATES, 94502 |
| OfficialSite | https://www.exelixis.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-09-30 |
| MarketCapitalization | 11944516000 |
| EBITDA | 850002000 |
| PERatio | 18.64 |
| PEGRatio | 2.268 |
| BookValue | 8.06 |
| DividendPerShare | None |
| EPS | 2.38 |
| RevenuePerShareTTM | 8.29 |
| ProfitMargin | 0.296 |
| OperatingMarginTTM | 0.429 |
| ReturnOnAssetsTTM | 0.177 |
| ReturnOnEquityTTM | 0.306 |
| RevenueTTM | 2288218000 |
| GrossProfitTTM | 2211037000 |
| DilutedEPSTTM | 2.38 |
| QuarterlyEarningsGrowthYOY | 0.725 |
| QuarterlyRevenueGrowthYOY | 0.108 |
| AnalystTargetPrice | 44.94 |
| AnalystRatingStrongBuy | 2 |
| AnalystRatingBuy | 9 |
| AnalystRatingHold | 9 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | 18.64 |
| ForwardPE | 15.22 |
| PriceToSalesRatioTTM | 5.22 |
| PriceToBookRatio | 5.46 |
| EVToRevenue | 4.803 |
| EVToEBITDA | 12.93 |
| Beta | 0.413 |
| 52WeekHigh | 49.62 |
| 52WeekLow | 31.9 |
| 50DayMovingAverage | 40.39 |
| 200DayMovingAverage | 39.76 |
| SharesOutstanding | 268112000 |
| SharesFloat | 228204000 |
| PercentInsiders | 2.194 |
| PercentInstitutions | 97.628 |
| ExDividendDate | None |
| dateChecked | 2025-12-21 23:37:03 |
| fresh | 1 |